nitrosamines – Page 3

Nitrosamine risk assessment incomplete during regulatory inspection – CAPA for nitrosamine findings

Navigating Incomplete Nitrosamine Risk Assessments during FDA, EMA, and MHRA Inspections Nitrosamines have become prominent risk factors in pharmaceutical manufacturing, especially concerning raw materials. Regulatory bodies like the FDA, EMA,…

Supplier nitrosamine control weak during risk assessment – risk mitigation and control strategy

Addressing Weak Supplier Nitrosamine Controls During Risk Assessments: A Playbook for Action In today’s pharmaceutical landscape, the occurrence of nitrosamines in raw materials poses a serious compliance and safety challenge.…

Nitrosamine risk assessment incomplete during regulatory inspection – preventing product recall

Navigating the Challenges of Incomplete Nitrosamine Risk Assessments During Regulatory Inspections In today’s pharmaceutical landscape, the assessment of nitrosamine risk is a critical component that can mean the difference between…

Risk mitigation plan inadequate during regulatory inspection – inspection-ready justification

Mitigating Risks During Regulatory Inspections: Developing an Inspection-Ready Plan The challenge of maintaining compliance during regulatory inspections can be daunting, especially for organizations managing the risks associated with raw materials…

Analytical method sensitivity questioned during ongoing surveillance – preventing product recall

Preventing Product Recall by Addressing Concerns Over Analytical Method Sensitivity In today’s pharmaceutical manufacturing landscape, maintaining the integrity of analytical methods is crucial, particularly as concerns around nitrosamine contamination and…

Risk mitigation plan inadequate during supplier audit – preventing product recall

Mitigating Risks during Supplier Audits to Prevent Product Recalls In the pharmaceutical industry, ensuring the quality and safety of raw materials is paramount. An inadequate risk mitigation plan during supplier…

Regulatory query on nitrosamines during regulatory inspection – preventing product recall

Effective Management of Nitrosamines During Regulatory Inspections to Prevent Product Recalls The emergence of nitrosamines as a critical regulatory focus has raised alarms within pharmaceutical manufacturing, particularly during inspections. The…

Risk mitigation plan inadequate during risk assessment – CAPA for nitrosamine findings

Addressing Inadequate Risk Mitigation Plans During Nitrosamine Risk Assessments The pharmaceutical industry faces an ongoing challenge with nitrosamine impurities found in raw materials, which can jeopardize product integrity and patient…

Potential nitrosamine source identified during risk assessment – risk mitigation and control strategy

Identifying Risks of Nitrosamines in Raw Materials: A Comprehensive Playbook In the evolving landscape of pharmaceutical manufacturing, the presence of nitrosamines poses substantial concerns. As regulatory bodies like the FDA…

Nitrosamine risk assessment incomplete during ongoing surveillance – FDA/EMA nitrosamine expectations

Addressing Incomplete Nitrosamine Risk Assessments During Ongoing Surveillance The pharmaceutical industry continues to grapple with the challenges posed by nitrosamines, particularly in the context of ongoing surveillance. Regulatory bodies like…

Nitrosamine risk assessment incomplete during risk assessment – preventing product recall

How to Address Incomplete Nitrosamine Risk Assessments to Prevent Product Recalls In recent years, the pharmaceutical industry has faced significant scrutiny concerning the presence of nitrosamines in drug products, stemming…

Risk mitigation plan inadequate during ongoing surveillance – inspection-ready justification

Addressing Inadequate Risk Mitigation Plans During Surveillance: A Comprehensive Playbook In the evolving landscape of pharmaceutical manufacturing, the risks associated with raw materials—especially concerning nitrosamines—are pressing. A recent uptick in…